NCT03267329

Duowell® vs. Telmisartan Monotherapy in Mild Dyslipidemia Patients With Hypertension

A Randomized, Open, Parallel, Multicenter, Phase 4 Study to Evaluate the Central Aortic Pressure Effect Between Fixed Dose Combination (Duowell® Tab) and Monotherapy of Telmisartan in Mild Dyslipidemia Patients With Hypertension

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: Yuhan Corporation · Industry
• Sex: All
• Age: 40 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is to evaluate effect and safety on central blood pressure with Duowell compared to telmisartan monotherapy in mild dyslipidemia patients with hypertension during 16 weeks.

Conditions

• Hypertension
• Dyslipidemia

Interventions

Type	Name	Description
DRUG	Duowell®	telmisartan 80mg/rosuvastatin 10mg for ASCVD risk=5%\~7.5% or telmisartan 80mg/rosuvastatin 20mg for ASCVD risk≥7.5%
DRUG	Telmisartan	telmisartan 80mg

Timeline

• Start date: 2017-09-11
• Primary completion: 2020-09-02
• Completion: 2020-09-02
• First posted: 2017-08-30
• Last updated: 2021-04-06

Locations

1 site across 1 country: South Korea